Vascular

Tenaxis Medical®, Inc. Receives FDA Approval for its ArterX® Surgical Sealant (via PR Newswire) MOUNTAIN VIEW, Calif., March 4, 2013 … continue reading “FDA Approval For Tenaxis Medical® ArterX® Surgical Sealant”

Medtech company Mercator says achieveing CE Mark approval for its Cricket™ and Bullfrog® Micro-Infusion Catheters clears pathway for launch of adventitial drug delivery technique into European Peripheral Artery Disease Market.

Covidien has completed patient enrollment in its iliac stent clinical study series. The series is composed of two prospective, multinational, multicenter studies – VISIBILITY Iliac and DURABILITY Iliac.

Lombard Medical Technologies PLC has announced that its Aorfix™ endovascular stent graft has been approved for commercial sale in the U.S. by the FDA. Aorfix™ is now the only endovascular stent graft licensed in the U.S. for use in more challenging cases with neck angulations greater than 60 degrees.

“Super therapy” renal denervation may favourably impact major cardiac events and a new study hopes to demonstrate to what extent. We’ll be fascinated to see the results and are betting the house on the fact that there is a positive effect.

Medtronic, the global leader in the $2 billion per year fast growing Aortic Endografts Market is rumoured to be about to increase its stake by acquiring new paradigm shifting technology that addresses the under-served needs of patients thoraco-abdominal aneurysms

Does anyone inside the industry really know what the future holds for Renal Denervation? It’s a technology that is just at the starting line and very much entering shake-out phase. We’ve no idea what the market will look like in 2021, but this new report promises crystal ball properties.

Cardiva Medical, Inc. has gained an FDA Premarket Approval (PMA) for the VASCADE Vascular Closure System (VCS). Clinical data demonstrated that the VASCADE VCS is clinically and statistically superior in both safety and efficacy compared to manual compression for patients undergoing percutaneous procedures through the femoral artery.

IDEV Technologies is trumpeting results from a newly published study which suggest that its Supera stent could be a treatment option for patients that would not have been offered a standard nitinol stent for popliteal artery disease.

St.Jude will be hoping that a new study of different degrees of hypertension may expand the indication for its EnligHTN renal denervation technology for hypertension to new patient populations.

VHS/Betamax/Bluetooth/DVD/Ultrasound/RF? It seems like we’re approaching a technology stand-off in the growing world of renal denervation. Ultrasound advocates claim advantages in reaching the nerves RF can only reach by heating things up a bit too much.

Gore launches a new sheath design in Europe, which it says delivers easier insertion and removal of endovascular devices for AAA and TAA.

Medtronic, Inc. has announced the CE mark and international launch of its Complete SE (self-expanding) vascular stent for use in the lower extremities, specifically the superficial femoral arteries and proximal popliteal arteries.

Vascular device company AngioDynamics has exercised its option to purchase certain assets of Microsulis Medical Ltd. including a leading microwave ablation technology and its worldwide distribution rights.

Covidien has gained CE Mark approval for its EverFlex™ Self-expanding Peripheral Stent with Entrust™ Delivery System which it says is designed to allow physicians to consistently place stents in the desired location with accuracy and ease.

Ruptured abdominal aortic aneurysms (AAAs) repaired using endovascular techniques may save more lives than surgical repair according to a new Irish analysis, which claims that at 30 days, aneurysm-related survival was 70% for patients treated with endovascular aortic repair (EVAR) compared with 33% for patients who underwent open surgical repair.